27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
The "Drug Analysis: Dexferrum" drug pipelines has been added to ResearchAndMarkets.com's offering.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Dexferrum (iron dextran; Luitpold Pharmaceuticals) is an intravenous (IV) iron maintenance treatment used to help elevate hemoglobin levels in patients with anemia in chronic kidney disease (CKD).
The iron is transported via transferrin to erythroid precursor cells. Erythroid precursor cells incorporate the iron into hemoglobin as the cell matures into a red blood cell. Dexferrum, and other iron therapies, are often used in combination with erythropoiesis-stimulating agent (ESA) therapies to increase the number of patients able to achieve target hemoglobin levels compared to patients on ESA therapies alone (Singh, 2008).
Dexferrum has a significantly less attractive clinical and commercial profile compared to more recent IV iron therapies, Injectafer (ferric carboxymaltose; Vifor/Luitpold Pharmaceuticals/Zeria), Venofer (poly-nuclear iron (III)-hydroxide in sucrose; Vifor/Luitpold Pharmaceuticals), and Feraheme (ferumoxytol; AMAG Pharmaceuticals), due to increased risk of iron toxicity and a highly inconvenient dosing strategy.
Key Topics Covered:
Product Profiles
FREE REPORT: How To Learn Options Trading Fast
In this special report, you will learn the four best strategies for trading options, how to stay safe as a complete beginner, a 411% trade case study, PLUS how to access two new potential winning options trades starting today.Claim Your Free Report Here.
Dexferrum: Anemia in chronic kidney disease
List of Figures
Figure 1: Dexferrum sales for anemia in chronic kidney disease across the five major EU markets, by country, 2015-24
List of Tables
Table 1: Dexferrum sales for anemia in chronic kidney disease across the five major EU markets, by country (NYSE:M), 2015-24
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/wcqcd2/dexferrum_iron?w=4
View source version on businesswire.com: http://www.businesswire.com/news/home/20180220006358/en/
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.